PYLARIFY is indicated for patients with suspected prostate cancer metastasis who are potentially curable via surgery or other therapy. Patients are considered for PSMA if a blood test shows high levels of PSA. If there is a high PSA level then a doctor may order the PSMA test. It is also indicated for patients with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.
“PSMA-targeted imaging has emerged as a valuable tool not only for the staging of prostate cancer, but also for restaging in men with recurrent disease,” said Michael Lasser M.D., medical director, robotic surgery, JFK University Medical Center. “With its higher specificity and enhanced spatial resolution, compared to conventional modalities, PSMA-targeted PET imaging is a significant advance in prostate cancer diagnostic.”
“The availability of the PYLARIFY test at JFK University Medical Center means patients with prostate cancer no longer need to travel to obtain PSMA-targeted PET imaging. They can get this innovative technology close to home,” said Amie Thornton, president, chief hospital executive, JFK University Medical Center.
“We customize a unique treatment approach for each patient,” says Hank Freeman, M.D., chair, radiology, JFK University Medical Center. “By combining PSMA PET imaging with advanced technology that uses biology to guide the delivery of radiation therapy we will help improve patient outcomes.”
Click here for demonstration on how Pylarify works on patients.